Text Size

Intravenous Gammaglobulin for Sickle Cell Pain Crises

This study is currently recruiting participants.
Verified December 2012 by Albert Einstein College of Medicine of Yeshiva University
Sponsor:
Collaborator:
Food and Drug Administration (FDA)
Information provided by (Responsible Party):
Deepa Manwani, Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:
NCT01757418
First received: November 8, 2012
Last updated: December 21, 2012
Last verified: December 2012
History of Changes
  Purpose

The purpose of this study is to determine whether intravenous immune globulin is safe and effective in the acute treatment of pain crises in sickle cell disease.


Condition Intervention Phase
Sickle Cell Disease
Pain
 Drug: Immune Globulin Intravenous
Drug: Normal saline
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Albert Einstein College of Medicine of Yeshiva University:

Primary Outcome Measures:
  • Duration of pain crisis [ Time Frame: Number of days from study drug infusion to end of crisis, average 4 days and maximum 30days ] [ Designated as safety issue: No ]
    End of crisis defined as either 1) Pain score consistently ≤ 5 (on the visual analog or Wong-Baker FACES scale) AND off of IV opioids or 2) Hospital discharge


Secondary Outcome Measures:
  • Total opioid use in equivalent of mg of IV morphine [ Time Frame: From study drug infusion to end of crisis, average 4 days and maximum 30days ] [ Designated as safety issue: No ]
    End of crisis defined as either: 1)Pain score consistently ≤ 5 (on the visual analog or Wong-Baker FACES scale AND off of IV opioids or 2) Hospital discharge


Estimated Enrollment: 60
Study Start Date: November 2008
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Immune Globulin Intravenous
IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg.
 Drug: Immune Globulin Intravenous
A single dose of intravenous immune globulin or saline placebo administered within 18 hours of hospital presentation. The current maximum dose planned is 800 mg/kg.
Other Name: GAMUNEX (Talecris Biotherapeutics)
Placebo Comparator: Normal saline
An equivalent volume (weight-based)of normal saline
 Drug: Normal saline

  Eligibility

Ages Eligible for Study:   12 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented diagnosis of sickle cell disease (SS or S-β thalassemia genotype)
  • Age 12-65 years
  • Uncomplicated acute pain episode requiring hospital admission and parenteral narcotics

Exclusion Criteria:

  • Increased stroke risk as assessed by transcranial Doppler or magnetic resonance imaging (all subjects undergo testing)
  • Concomitant acute process, including fever > 38.5° C with clinical suspicion of infection
  • Increased ALT > 2X ULN
  • Serum creatinine ≥1.3 mg/dL, >300 mg/dL protein in spot urinalysis, or known condition associated with renal dysfunction
  • Hb > 10 g/dL and Hct > 30%
  • Known IgA deficiency or known allergy to gamma globulin
  • Pregnancy or breastfeeding
  • Vaccination with a live attenuated virus in the preceding 6 weeks
  • Documented history of illicit (eg. heroin, cocaine) drug abuse or drug-seeking behavior
  • Current participation in another investigational drug study
  • Current treatment with chronic transfusion
  • Prior thromboses or current estrogen use
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01757418

Contacts
Contact: Deepa G Manwani, M.D 718-741-2342 dmanwani@montefiore.org
Contact: Karen Ireland 718-741-2401 kireland@montefiore.org

Locations
United States, New York
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10467
Contact: Deepa G Manwani, MD     718-741-2342     dmanwani@montefiore.org    
Principal Investigator: Deepa G Manwani, MD            
Sponsors and Collaborators
Albert Einstein College of Medicine of Yeshiva University
Food and Drug Administration (FDA)
Investigators
Principal Investigator: Deepa G Manwani, M.D Albert Einstein College of Medicine of Yeshiva University
  More Information

Publications:

Responsible Party: Deepa Manwani, Director, Sickle Cell Disease Program, Children's Hospital at Montefiore, Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier: NCT01757418     History of Changes
Obsolete Identifiers: NCT00644865
Other Study ID Numbers: 7R01FD003447-03
Study First Received: November 8, 2012
Last Updated: December 21, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Albert Einstein College of Medicine of Yeshiva University:
Sickle Cell Disease
Pain
Immune Globulin

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Gamma-Globulins
 Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013